NCT07658573Active, not recruiting
AI Multimodal Model for Predicting CRPC Progression Risk
Artificial Intelligence for Predicting Progression Risk of Castration-Resistant Prostate Cancer by Integrating Multimodal Data: A Multicenter, Retrospective Study
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease. The study will use pre-treatment MRI images, biopsy pathology slides, and clinical data collected from patients who received either hormone therapy (ADT) or radical prostatectomy surgery. By integrating these different types of data, the AI model is designed to help doctors identify high-risk patients earlier, personalize treatment plans, and ultimately improve patient outcomes. This is a multicenter, retrospective study that will analyze data from over 500 patients with at least 24 months of follow-up. The performance of the model will be evaluated using standard accuracy metrics.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 14 Jun 2026
- Start date
- 1 Jun 2025
- Primary completion date
- 1 Jun 2028
- Lead sponsor
- Guangxi Medical University
- Diseases
- Prostate cancer
- NCT number
- NCT07658573
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Jun 2025 to the primary completion date, 1 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- (1) Missing clinical information; (2) MRI images of poor quality or missing key sequences; (3) Poor quality pathological specimens; (4) Lost to follow-up or incomplete data during follow-up; (5) Concurrent other malignant tumors; (6) Prior anti-tumor therapy.
Who the study is looking for
- (1) Male, age ≥18 years; (2) Pathologically confirmed newly diagnosed advanced prostate cancer; (3) Received at least 6 months of androgen deprivation therapy OR underwent radical prostatectomy; (4) Have complete baseline MRI (T2WI, DWI, ADC) and biopsy pathology data; (5) Have complete follow-up records (at least 24 months).
Age in the registry: 18 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guangxi Medical University First Affiliated Hospital Coordinator of this site? Confirm its status | Nan'ning | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.